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Transgender adults, gender-affirming hormone
therapy andblood pressure: a systematic review
Paul J. Connelly, Anna Clark, Rhian M. Touyz, and Christian Delles
Objectives: Gender-affirming hormone therapy (GHT) is
utilized by people who are transgender to align their
secondary sex characteristics with their sex identity. Data
relating to cardiovascular outcomes in this population are
limited. We aimed to review the impact of GHT on the
blood pressure (BP) of transgender individuals.
Methods: We searched PubMed/MEDLINE, SCOPUS and
Cochrane Library databases for articles published relating
to the BP of transgender adults commencing GHT.
Methodological quality was assessed via the ‘Quality
Assessment Tool for Before–After (Pre–Post) Studies with
No Control Group’.
Results: Six hundred articles were screened, of which 14
studies were included in this systematic review encompassing
1309 individuals (50% transgender men and women)
treated with GHT between 1989 and 2019. These articles
were all pre–post observational studies without control
groups. Mean ages ranged between 23.0–36.7 years
(transgender men) and 25.2–34.8 years (transgender
women). Interventions were diverse and included oral,
transdermal and injectable hormonal preparations with 4
months to 5 years follow-up. Most studies in transgender
men did not demonstrate a change in BP, whereas
transgender women on GHT demonstrated an increase in SBP
but not DBP. These studies were heterogenous with
significant methodological limitations and only two were
determined to have a good quality rating.
Conclusion: There is currently insufficient data to advise
the impact of GHT on BP in transgender individuals. Better
quality research is essential to elucidate whether
exogenous sex hormones modulate BP in transgender
people and whether this putative alteration infers poorer
cardiovascular outcomes.
Keywords: blood pressure, estrogen, testosterone,
transgender
Abbreviations: BP, blood pressure; GHT, gender-affirming
hormone therapy; GnRH, gonadotropin-releasing hormone;
VSMC, vascular smooth muscle cell
INTRODUCTION
T
ransgender people experience sex dysphoria due to
incongruence between their sex identity and the sex
they were assigned at birth [1]. Gender-affirming
hormone therapy (GHT), including testosterone, estrogen,
gonadotropin-releasing hormone (GnRH) analogues and
antiandrogens, aims to align the characteristics of transgen-
der people with their sex identity [1].
The recent substantive increases in population preva-
lence of transgender people requires the implementation of
evidence-based guidance to better protect the health of this
population [2–4]. However, due to a paucity of epidemio-
logical and mechanistic data, there is considerable uncer-
tainty surrounding the impact of GHT on the cardiovascular
health of transgender individuals [5–7]. Existing data sug-
gest that the use of estrogens in transgender females confers
an increased risk of myocardial infarction and ischemic
stroke. Conversely, transgender males receiving testoster-
one lack any consistent or convincing evidence of
increased risk of cardiovascular or cerebrovascular disease
[7]. However, in the absence of randomized controlled trials
or comprehensive prospective longitudinal studies, ambi-
guity remains regarding whether such risk exists, and by
which interventions this risk can be ameliorated.
Consequently, international guidelines, set out by the
Endocrine Society and World Professional Association for
Transgender Health, have been cautious in their recommen-
dations regarding modifiable risk factors for cardiovascular
disease in this population [8,9]. Hypertension remains the
most important modifiable risk factor for the development of
cardiovascular disease. Therefore, these organizations have
not unreasonably recommended that blood pressure (BP) is
monitored in transgender people receiving GHT. However,
these guidelines do not provide any indication of the effect
size of this treatment on BP, treatment targets for this patient
group, or the levels of evidence for this recommendation.
A comprehensive overview is therefore required to
assess the impact of GHT on the BP. Our aim was to
perform a systematic review of the relationship of exoge-
nous sex hormones and SBP and DBP in transgender men
and women commencing treatment.
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METHODS
Eligibility criteria
We included randomized trials and observational studies of
transgender individuals who used GHT regardless of sex-
reassignment surgery status. Eligible studies included trans-
gender men prescribed testosterone and transgender
women prescribed estrogen, antiandrogens (cyproterone
acetate, finasteride or spironolactone) or GnRH agonists.
Studies were included regardless of dose of GHT. Studies
were required to provide a comparison of BP before and
after/during treatment for a minimum of 3 months. Articles
with participants under the age of 16 were excluded in
addition to review articles, commentaries and letters that
did not contain original data. BP measurements could
include manual, automated or ambulatory recordings.
Many transgender individuals receiving GHT may be sex-
non binary (e.g. their sex identity or expression does not
confirm to typical binary sex), and may not consider them-
selves as simply men or women [3]. However, for the
purposes of this systematic review, transgender people
treated with estrogen (with or without antiandrogens and
GnRH analogues) were considered transgender women,
whereas transgender individuals treated with testosterone
were considered transgender men.
Search strategy
The current systematic review adhered to the Preferred
Reporting Items for Systematic Reviews guidelines [10].
PubMed/MEDLINE, SCOPUS and Cochrane Library data-
bases were searched for articles published until 13 January
2020. The search was limited to English language articles.
The following medical subject headings were used in the
search: blood pressure AND transgender OR ‘transgender
person’ OR ‘person, transgender’ OR ‘persons, transgender’
OR ‘transgender persons’ OR ‘transmasculine’ OR ‘trans-
feminine’ OR ‘trans masculinization’ OR ‘trans feminization’
OR ‘gender incongruent’ OR ‘gender dysphoric’ OR ‘gender
affirming’ OR ‘transsexual persons’ OR ‘person, transsexual’
OR ‘persons, transsexual’ OR ‘transsexual person’ OR ‘trans-
gender male’ OR ‘transgender female’ OR ‘transgender man’
OR ‘transgender woman’ OR ‘trans man’ OR ‘trans woman’
OR ‘cross-sex’.
Data extraction, outcome and quality
The literature search, data extraction and quality assess-
ment were conducted independently by two investigators
(P.J.C. and A.C.). In the case of disagreement between the
two reviewers, consensus was achieved after consulting
with a third reviewer (C.D.). Duplicate records were
removed and study titles and abstracts were screened to
identify potentially eligible articles for inclusion in the full
text review. The selected articles were read in full for
confirmation of eligibility and data extraction. Data
extracted from these articles included name of the first
author, publication year, country, number of participants,
duration of the follow-up, intervention (dose and therapy),
and SBP and DBP before and after the introduction of GHT.
To determine the quality of the included studies the
National Institute of Health Quality Assessment Tool for
Before–After (Pre–Post) Studies with No Control Group
was utilized [11]. This tool is comprised of 12 questions used
to assess the risk of types of bias, such as selection,
reporting or observer bias. The methodological quality of
included studies was assessed by two authors (P.J.C. and
A.C.) separately. Each study was defined as poor, fair or
good based on the answers compiled from this tool. To
determine the level of agreement between assessing
authors, Cohen’s kappa was calculated [12]. A score less
than 0.4 is considered poor, between 0.4 and 0.8 fair to
substantial, and above 0.8 as almost perfect interrater
agreement. A meta-analysis of uncontrolled pre–post stan-
dardized mean differences in BP was not performed as they
lack independence and fail to discern between intra-indi-
vidual and interventional effects [13].
RESULTS
Study selection and characteristics
Our multidatabase literature search identified 600 nondu-
plicated potentially relevant records (Fig. 1). No records
were identified through other resources. Following the
screening of these records’ titles and abstracts, 84 full text
articles were assessed for eligibility; however, 70 articles
were excluded due to not being original investigations, not
assessing relevant outcomes, not obtaining pre-GHT out-
come measurements [14] or including adolescent popula-
tions [15–18].
Consequently, 14 studies were included in this system-
atic review encompassing 1309 individuals (50% trans-
gender men and women) treated with GHT between 1989
and 2019. Follow-up ranged between 4 months and 5 years.
11 of the included studies were undertaken in Europe and
three in North America. Mean ages ranged between 23.0–
36.7 years in transgender men and 25.2–34.8 years in
transgender women.
Of the included studies, all studies were pre–post obser-
vational studies without control groups. Only one study
provided the device used to measure BP (BP-8800; Colin
Corporation, Hayashi, Japan) [19], the position of measure-
ment was acknowledged in four studies [19–21], and the
use of multiple BP measurements mentioned in three
studies [19,20,22].
Transgender men
Between 2003 and 2019 a total of 13 studies measured the
SBP and DBP of transgender men receiving GHT (Table 1).
Mean follow-up time was 18.9 (SD 14.2) months (range 4–
60 months). The average sample size was 50; however,
three studies recruited less than 20 individuals [19,23,24].
Various formulationsof testosteronewere administered in
these studies including intramuscular testosterone undeca-
noate (n¼ 8), intramuscular testosterone esters (n¼ 7),
transdermal testosterone gel (n¼ 2) or patches (n¼ 1), oral
testosterone undecanoate (n¼ 1), or subcutaneous testos-
terone cypionate (n¼ 1). One study did not specify the
formulation of intramuscular testosterone administered [23].
As demonstrated in Table 1, the effect of testosterone
GHT on BP varies considerably between these studies. The
majority of these studies did not demonstrate a significant
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change in SBP (n¼ 9), whereas four studies reported a
significant decrease in SBP ranging between 5.2 and
13.3 mmHg [20,24,27,28] and only one study reported a
significant increase in SBP (4.6 mmHg) [22]. Only Auer et al.
[28] demonstrated a 3.4-mmHg fall in DBP following 12
months of intramuscular testosterone undecanoate.
Transgender women
Table 2 summarizes included studies (n¼ 10) of transgen-
der women receiving estrogen therapy comprising of 661
individuals. These studies were undertaken between 1989
and 2019 with a mean follow-up of 16.4 (SD 7.9) months
(range 6–31.7 months). The mean sample size of these
studies was 66 individuals, with the largest being conducted
by van Velzen et al. [21] of 242 individuals.
The doses and formulations of GHT vary significantly
between studies. Oral estradiol valerate (n¼ 6), estradiol
patches (n¼ 6), estradiol gel (n¼ 2), oral ethynyl estradiol
(n¼ 2), oral conjugated estrogen (n¼ 2), sublingual
micronized 17b estradiol (n¼ 1), intramuscular estradiol
valerate (n¼ 2) and unspecified oral estrogen (n¼ 1), were
utilized. Four studies provided transdermal estrogen
patches rather than oral estrogen to those over the age
of 40–45 years [21,28,30,31]. The most common antiandro-
gen was cyproterone acetate (n¼ 7), whereas spironolac-
tone (n¼ 3) and flutamide (n¼ 1) was also utilized. No
study incorporated the use of GnRH analogues while two
studies utilized progestogens.
The outcomes relating to these studies are also diverse;
however, the majority of studies (n¼ 5) demonstrated a rise
in SBP following the introduction of GHT in transgender
women, ranging between 6 and 10mmHg [21,23,24,28,32].
Two studies demonstrated a fall in SBP (6.4 to
17.8 mmHg) [20,31]. DBP was reduced in three studies
(3.2 to 5.7 mmHg) [19,20,31], whereas three other stud-
ies demonstrated an increase (1.7–11.0 mmHg) [23,28,32].
Quality of evidence
Quality of methodology was assessed using the Quality
Assessment Tool for Before–After Studies with no control
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FIGURE 1 Flow diagram for study selection.
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group (Table 3). Inter-rater (P.J.C. and A.C.) agreement was
92.8% with an expected agreement of 69.4% and Cohen’s
kappa of 0.77 (standard error, 0.22), indicating substantial
agreement. Only two studies were determined to have a
good quality rating [20,21], however, as uncontrolled pre–
post studies demonstrate weak evaluative designs, no study
successfully fulfilled the entire quality criteria. Largely,
studies did not provide power calculations or were under-
powered to demonstrate significant changes in BP. Further-
more, studies did not report blinding, lacked multiple
measurements before and after the introduction of GHT
and comprised of significantly heterogenous groups
receiving various doses, formulations and combinations
of GHT treatments.
DISCUSSION
The aim of this systematic review was to gain insights on the
effects of GHT on BP of transgender men and women. This
systematic review has examined the available evidence
relating to BP alteration in this population. Overall, we
have identified 14 studies relating to transgender people
receiving GHT, who demonstrated pre and post GHT
BP measurements.
TABLE 1. Blood pressure in testosterone exposed transgender men
Mean difference (mmHg) [95% CI]
Reference Country
Follow-up
(months)
Sample
size, n
Mean age
(years) (SD) Intervention SBP DBP
Elbers et al. [19] The Netherlands 12 17 23 (5) 250 mg IM testosterone esters/
2 weeks
1.0 [7.1, 5.1] 0.2 [4.1, 4.5]
Giltay et al. [22] The Netherlands 4 81 36.7 (10) 250 mg IM testosterone esters/
2 weeks (n¼61) or oral
testosterone undecanoate
160–240 mg/day (n¼20)
4.6 [0.9, 8.3] 2.1 [0.2, 4.4]
Mueller et al. [25] Germany 12 35 29.6 (8.9) 1 g IM testosterone
undecanoate/12 weeks
4.3 [10.1, 1.5] 2.9 [6.1, 0.3]
Mueller et al. [27] Germany 24 45 30.4 (9.1) 1 g IM testosterone
undecanoate/12 weeks
5.2 [9.9, 0.5] 2.8 [5.6, 0.0]
Wierckx et al. [30] Belgium, The
Netherlands
12 53 24.5 (7.0)a 1 g IM testosterone
undecanoate at baseline,
then 6 weeks, then/12
weeks thereafter. If
intolerant of testosterone
undecanoate, 250 mg IM
testosterone esters/2 weeks
4.1 [8.7, 0.5]a 2.3 [6.1, 1.5]a
Colizzi et al. [20] Spain 24 43 28.8 (5.6) 250 mg IM testosterone ester/
21.163.17 days
13.3 [17.0, 9.6] 1.4 [4.9, 2.1]
Quiro´s et al. [31] Spain 24 97 28.6 (8.6) 50 mg transdermal testosterone
gel/day or 1 g IM
testosterone undecanoate
1 g/12 weeks
2.2 [5.4, 1.0] 1.5 [4.1, 1.1]
Deutsch et al. [32] USA 6 34 27 (6.9) 50–70 mg subcutaneous
testosterone cypionate/week
(n¼31), 5 g testosterone gel/
day (n¼2) or 4 mg
testosterone transdermal
patch/day (n¼1)
3.0 [9.7, 3.7]b 2.0 [2.0, 6.0]b
Fernandez and
Tannock [23]
USA 18 19 27 (7) 150 mg IM testosterone/2
weeks (type unspecified)
2.0 [0.9, 4.9] 1.0 [1.4, 3.4]
Vita et al. [24] Italy 25.5c 11 25.1 (3.7) IM testosterone enanthate
(n¼10) or undecanoate
(n¼1) (dose/frequency
unspecified)
6.2 [11.9, 0.6] 3.1 [8.1, 1.9]
Auer et al. [28] Germany 12 45 27.5 (1.3) 1 g IM testosterone
undecanoate/12 weeks
7.2 [8.7, 5.7] 3.4 [4.4, 2.5]
Gava et al. [26] Italy 60 50 30.1 (6.1)a 1 g IM testosterone
undecanoate at baseline,
then 6 weeks, then/12
weeks thereafter (n¼25) or
250 mg IM testosterone
enanthate/3–4 weeks
(n¼25)
3.0 [0.6, 6.6]a 1.5 [1.6, 4.6]a
van Velzen et al. [21] Belgium, The
Netherlands
12 118 26.4 (9.1) 1 g IM testosterone
undecanoate/12 weeks
(n¼79) or 250 mg IM
testosterone esters/2 weeks
(n¼62) or 50 mg
testosterone gel/day (n¼47)
1.5 [4.7, 1.7]d 1.8 [4.1, 0.5]d
95% CI, 95% confidence interval; IM, intramuscular.
aPooled means SD.
bData extracted from median and IQR.
cMean follow-up of cohort.
dData derived from percentage change in baseline values after adjustment for age, SD derived from 95% CI.
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Our findings demonstrate that current evidence is
derived from uncontrolled pre–post studies, which are
heterogenous in their recorded interventions and lack
consistency in their outcomes. The majority of studies
included in this systematic review demonstrate poor to fair
quality, even after taking into account the limitations of
uncontrolled study designs. Other common weaknesses
include short follow-up durations, lack of standardization
in delivery of GHT and small sample sizes, thereby limiting
their power. Only one study provided information
TABLE 2. Blood pressure in estrogen exposed transgender women
Mean difference (mmHg) [95% CI]
Reference Country
Follow-up
(months)
Sample
size, n
Mean age
(years) (SD) Intervention SBP DBP
Prior et al. [29] Canada 12 23 30.7 (6.2) 0.625 mg increasing to 2.5 mg
conjugated estrogen twice daily for
3/4 weeks, followed by 10 mg
medroxyprogesterone/day during
weeks 3 and 4 or continuously if
gonadotrophins increased, to aid in
testosterone reduction or breast
development, in addition 100–
200 mg spironolactone/day
7.3 [0.7, 15.3]a 2.6 [4.1, 9.3]a
Elbers et al. [19] The Netherlands 12 20 26 (6) 100mg oral ethinyl estradiol and
100 mg cyproterone acetate/day
7.2 [14.4, 0.0] 5.7 [11.1, 0.3]
Wierckx et al. [30] Belgium, The
Netherlands
12 53 30.3 (14.1)e <45 Years (n¼40) 4 mg oral estradiol
valerate and 50 mg cyproterone
acetate/day. >45 Years (n¼13)
100mg/24 h transdermal 17b
estradiol patch. If intolerant of this,
2 mg transdermal 17b estradiol gel
twice daily or 4 mg estradiol valerate
per day
5.4 [0.0, 10.8]e 0.1 [3.8, 4.0]e
Colizzi et al. [20] Spain 24 79 30.2 (9.6) 2.120.57 mg transdermal estradiol
gel/day and 100 mg cyproterone
acetate/day
17.8 [21.2, 14.4] 3.2 [6.1, 0.3]
Quiro´s et al. [31] Spain 24 150 32.4 (10.1) Oral estrogen (conjugated equine
estrogens or estradiol valerate) and
either cyproterone acetate or
flutamide. >40 Years were
recommended transdermal estrogens
(dose/frequency/formulation
unspecified)
6.4 [9.3, 3.5] 3.7 [6.0, 1.4]
Deutsch et al. [32] USA 6 16 29 (9.4) 2 mg sublingual micronized 17b
estradiol twice daily (n¼14) or
20 mg IM estradiol valerate/2 weeks
(n¼1) or 100mg estradiol via
transdermal patch (n¼1) in addition
to 50–100 mg spironolactone/day
(n¼15)
10.0 [3.0, 17.0]b 11.0 [2.3, 19.7]b
Fernandez and
Tannock [23]
USA 18 33 31 (10) 1.71 mg oral estrogen (type
unspecified)/day (50%),
transdermal estrogen (dose/type/
frequency unspecified) (14%) or IM
estrogen (36%) (dose/type/frequency
unspecified), and 100 mg
spironolactone/day
6.0 [4.3, 7.7] 5.0 [3.8, 6.2]
Vita et al. [24] Italy 31.7c 21 25.2 (7) 2–6 mg oral estradiol valerate/day and
50–100 mg cyproterone acetate/day
(if not undergoing sex reassignment
surgery). Patients (n¼4) receiving
ethylestradiol were switched to
estradiol valerate. Progesterone was
also utilized (n¼3) (type/route/
frequency unspecified)
6.1 [1.2, 11.0] 4.00 [1.1, 9.1]
Auer et al. [28] Germany 12 24 34.8 (1.4) 2 mg oral estradiol valerate twice daily
or 100mg transdermal 17b estradiol
patch/day (if >45 years) and 50 mg
cyproterone acetate/day
6.7 [5.2, 8.2] 1.7 [0.8, 2.6]
van Velzen
et al. [21]
Belgium, The
Netherlands
12 242 32.3 (12.6) 2 mg oral estradiol valerate twice daily
(n¼144) or 100mg transdermal
estradiol patch/day (if age >45
years, n¼98), and 50 mg
cyproterone acetate/day
3.4 [0.4, 6.4]d 1.8 [0.5, 4.1]d
95% CI, 95% confidence interval; GHT, gender-affirming hormone therapy; IM, intramuscular.
aData included on participants not previously exposed to GHT.
bData extracted from median and IQR.
cMean follow-up of cohort.
dData derived from percentage change in baseline values after adjustment for age, SD derived from 95% CI.
ePooled means SD.
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regarding the device used to measure BP (Colin, BP-8800)
[19]. However, this device has been demonstrated to exhibit
inconsistent aberration patterns, thereby invalidating its use
in clinical research [33]. Lastly a meta-analysis is not possible
as such results lack independence and cannot discern
between intraindividual and GHT effects [13].
A limitation of this systematic review is that it did not
include cross-sectional assessments of the development of
hypertension. Asscheman et al. [34] observed an increase in
the crude incidence of hypertension in transgender women
but not men, and no difference in hypertension standard-
ized incidence ratio (defined as >160/95 mmHg) in either
groups when compared with cisgender populations. Fur-
thermore, self-reported hypertension in the Behavioral Risk
Factor Surveillance System survey has been found to be no
higher than cisgender populations [35]. Results from these
studies are also derived from relatively small populations
and rely on outdated or self-reported hypertension defi-
nitions, thereby limiting their utility.
As many as 390 adults per 100 000 of the US population
identify as transgender and this marginalized group suffer
from significant health disparities [3,36]. To enact better care
and evidence-based guidance for this expanding popula-
tion, the collection and reporting of good quality data are
imperative [1]. Randomized controlled trials reduce bias
and permit the examination of the causal inference of
an intervention, however, may not be permissible or ethical
in this population [1]. However, the risk of bias inherent
in the intrinsically weak evaluative quasiexperimental
uncontrolled before–after design could be reduced by
the introduction of cisgender controls (ideally both male
and females per transgender individual) or an interrupted
time series design, which would allow the intervention
effect to be estimated accounting for the underlying trend
[37]. Given the limited age groups that were assessed in
these studies, research focusing on the interaction between
advancing age and life-long GHT is also vital [38].
Furthermore, in line with recent guidance on BP assess-
ment in clinic-based research, it is recommended that
multiple BP readings be taken from a validated and cali-
brated BP device and averaged at each assessment [39].
Multiple visits with BP assessments are undertaken at
baseline and during intervention follow-up, which would
permit a simple interrupted time series design. The addition
of ambulatory BP monitoring should be encouraged.
The majority of studies of transgender men receiving
GHT did not demonstrate a significant change in BP,
whereas broadly there was an increase in SBP but not
DBP in transgender women receiving hormone therapy.
Mechanistically, estrogen promotes endothelium-depen-
dent vasorelaxation via increasing nitric oxide bioavailabil-
ity, expression and activation of endothelial nitric oxide
synthase, increases in endothelium-derived hyperpolariz-
ing factor and prostacyclin, and reductions in endothelin-1
[40–44]. Endothelium-independent vasodilation is
achieved by modulation calcium flux in the vascular
smooth muscle cells (VSMCs) [45]. Conversely, testosterone
may facilitate either vasodilatation or vasoconstriction via
TABLE 4. Gaps in evidence and recommendations for future research
Research question Recommendations for future research
Does GHT alter the blood pressure of
transgender men and/or women?
Interrupted time series or controlled cohort study measuring blood pressure before and after the introduction
of GHT using validated office or ideally ambulatory blood pressure recordings
Are alterations in blood pressure associated
with increased cardiovascular risk in
transgender men and women?
Prospective longitudinal observational cohort study of transgender people for cardiovascular disease in relation
to components of blood pressure
Do blood pressure-lowering interventions
reduce cardiovascular risk in transgender
men and women?
Randomized controlled study of transgender individuals with SBP>130 mmHg to SBP targets of <120 mmHg
(intensive treatment) or less than 140 mmHg (standard treatment) with a primary composite outcome of
myocardial infarction, other acute coronary syndromes, stroke, heart failure or death from cardiovascular
causes
GHT, gender-affirming hormone therapy.
TABLE 3. Quality assessment of studies assessing the effect of gender-affirming hormone therapy on blood pressure in transgender
individuals
Reference Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Quality rating
Prior et al. [29] Y Y Y Y NR N N NR Y Y N NA Fair
Elbers et al. [19] Y Y Y Y NR Y Y NR Y Y N NA Fair
Giltay et al. [22] Y Y Y Y N N Y N Y Y N NA Fair
Mueller et al. [25] Y Y Y Y NR Y N N Y Y N NA Fair
Mueller et al. [27] Y Y Y Y NR Y N N Y Y N NA Fair
Wierckx et al. [30] Y Y Y Y NR N N N Y Y N NA Fair
Colizzi et al. [20] Y Y Y Y Y Y Y N Y Y N NA Good
Quiro´s et al. [31] Y Y Y Y Y N N N N Y N NA Fair
Deutsch et al. [32] Y Y Y Y NR N Y N Y Y N NA Fair
Fernandez and Tannock [23] Y Y Y Y NR N N N N Y N NA Poor
Vita et al. [24] Y Y Y Y NR N Y N Y Y N NA Fair
Auer et al. [28] Y Y Y Y NR N N N Y Y N NA Fair
Gava et al. [26] Y Y Y Y NR N N N Y Y N NA Fair
van Velzen et al. [21] Y Y Y Y Y N Y N N Y N NA Good
N, no; NA, not applicable; NR, not reported; Y, yes.
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endothelium-independent inhibition of voltage-operated
calcium channels and activation of potassium channels in
VSMCs, and enhancing thromboxane A2-mediated and
endothelin-1-mediated vasoconstriction, respectively
[46,47]. Importantly, sex hormones may also indirectly
modulate vasodynamic pathways such as the renin–angio-
tensin–aldosterone system [48–50]. The putative relation-
ship between estrogen and elevated BP in transgender
women may highlight fundamental gaps in our understand-
ing of the vasoconstrictive properties of this sex hormone.
However, due to the limited quality of the of the studies
included in this review, there is insufficient data to deter-
mine meaningful conclusions regarding the effect of estro-
gen or testosterone-based GHT on the SBP or DBPs of
transgender individuals or advise clinically on this matter.
More robust research is required (Table 4) to determine
whether GHT mediates alterations in BP of transgender
individuals, whether this change is associated with
increased cardiovascular risk, and if such risk exists, what
interventions can be undertaken to improve the health of
transgender people.
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